News
EvE Bio partners with OpenAI Foundation on “AI for Alzheimer’s”
We are thrilled to partner with OpenAI Foundation on their AI for Alzheimer’s initiative . Alzheimer’s is exactly the kind of devastating, intractable problem where AI could make a real difference. Drug development for Alzheimer’s has been a challenge. Nearly 99% of…
With partners in Drug Target Review
Our work at EvE in conjunction with Convergent Research, DrugBank and Hugging Face was recently featured in Drug Target Review. This piece shows off the team effort to create high quality data and make it accessible to researchers. The aim of our work is described as…
Which compounds?
While our data generation efforts continue to expand across targets for our first compound library, we have started to design our second library. While our first library includes 1,300 FDA approved small molecule drugs and about 100 drug-adjacent compounds…
Putting Pharmome Data in Researchers’ Hands
Announcing New Developments
These are exciting times at EvE Bio. We’ve been busy these last two years establishing the largest available pharmome mapping dataset. Now it’s making its way into the world to drive real discoveries. I’m delighted to share several developments from our press release today that define this pivotal moment.
A deep dive on Owl Posting
Abhi Mahajan recently wrote a deep dive on our work at EvE on his blog Owl Posting, where he covers the intersection of biology and machine learning. This is, of course, an intersection that is right up our alley. He makes three arguments in this article that we…
Announcing data release #1!
Our pharmome mapping data is getting out into the world! With our first public data release, we.announce our commitment to continue to release data on a regular basis going forward. This release contains data for 19 nuclear receptors, each assayed in agonist and…
Why map the pharmome? (Part 2)
Part 2: For Drug Repurposing
Finding new ways to use old drugs can save billions of dollars and years of development time. Yet today such “drug repurposing” opportunities are mostly stumbled upon rather than systematically identified. Mapping the pharmome can change that.
Why map the pharmome? (Part 1)
Part 1: For Safer Drugs
A question frequently posed regarding pharmome mapping goes something like: “Don’t pharmaceutical companies already do that? Don’t they test each new drug to ensure it won’t act on any gene products other than the drug’s intended therapeutic target, to avoid ‘off-target side effects?’” The short answer is “yes, but no.”